.Attribute Medication, Posted online: 03 September 2024 doi:10.1038/ s41591-024-03223-zThis Standpoint calls for incorporation of individuals along with MASLD and measurement of liver results in cardio-- kidney-- metabolic trials, when information propose mechanistically plausible perks and scientific safety and security-- and outlines points to consider for trial layout as well as regulative commendation.